Real-world evidence of quality of life improvement in patients with distal ulcerative colitis treated by mesalazine: the Quartz study. Issue 12 (12th September 2022)

• Record Type: Journal Article
• Authors: Paupard, Thierry; Gonzalez, Florent; Caron, Bénédicte; Siproudhis, Laurent; Peyrin-Biroulet, Laurent
• Is Part Of: European journal of gastroenterology & hepatology. Volume 34:Issue 12(2022)
• Page Start: 1203
• Page End: 1209
• Publication Date: 2022-09-12
• Subjects: inflammatory bowel disease -- proctitis -- proctosigmoiditis -- prospective study -- Short Inflammatory Bowel Disease Questionnaire; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; Digestive organs -- Diseases; Liver -- Diseases; Periodicals; 616.33
• DOI: 10.1097/MEG.0000000000002444
• Languages: English
• ISSNs: 0954-691X

Abstract

Abstract : Background: Distal ulcerative colitis (UC) is responsible for distressing symptoms and reduces quality of life (QoL). Oral and topical formulations of 5-amino-salicylic acid are the first line therapy for mild to moderate distal UC. Objective: Our aim was to evaluate the impact of mesalazine treatment for mild to moderate ulcerative proctitis and proctosigmoiditis on patient QoL. Methods: Ninety-three patients with mild to moderate ulcerative proctitis and proctosigmoiditis, initiating a treatment with Pentasa, were prospectively included. The primary endpoint was the change from baseline to W8 in patient health-related QoL (HRQoL) as measured by the Short Inflammatory Bowel Disease Questionnaire (SIBDQ) total score. Results: More than 80% of patients were prescribed with a rectal formulation, either alone (47.9%) or with an oral formulation (35.1%), and 17.0% of patients were prescribed oral formulation alone. Mean SIBDQ score was improved at W8 in patients affected with mild and moderate disease ( P < 0.001 versus baseline in both groups, as well as in patients who achieved clinical remission ( P < 0.001). Patients who achieved clinical remission at W8 reached a mean change of +6.7 (±7.1), whereas those who did not achieve clinical remission had a mean change of +1.1 (±8.9). Seventy-five per cent of patients had an improvement of their disability index at W8. Fecal incontinence was also improved at W8. Conclusion: HRQoL measuring with the SIBDQ is proportionally related to disease activity in patients with distal UC treated with mesalazine.